Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.

To help spread the message that managing Type 2 diabetes “doesn’t have to be a solo act,” Eli Lilly, fittingly, is assembling ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Stonestreet was diagnosed with type 2 diabetes in 2009, but kept it a secret. He told Business Insider why he's speaking out ...

Modern Family’ alum Eric Stonestreet opened up to PEOPLE about living with type 2 diabetes and being unable to get a grasp on ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Lilly's weekly prescription data for Zepbound is up 354% year-over-year, while Novo's Wegovy is up just 61%. That's based on ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

First, he landed his role in "Modern Family," a critically acclaimed ABC sitcom that went on for 11 seasons and catapulted ...

Shares of Eli Lilly ( LLY -10.61%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as ...